Site Editors

Alexander Drilon, MD

Gregory J. Riely, MD, PhD

Advertisement

Advertisement

News

Impact of Genetic Differences in Treatment Response Among Black Individuals With Pancreatic Cancer

News

AACR 2023: Concordance Between Tissue-Based Testing Methods for Identifying NTRK Gene Fusion

News

AACR 2023: Researchers Identify Cell Signaling Pathways Activated by ETV6::NTRK3 Fusions

News

AACR 2023: Finnish Population–Based Study of NTRK Gene Fusions in Solid Tumors

News

AACR 2023: Researchers Identify Cell Signaling Pathways Activated by ETV6::NTRK3 Fusions

Medical Literature

Comparing the Performance of Pan-TRK Antibody Clones and Immunohistochemistry Assays

Medical Literature

Factors to Consider When Developing Laboratory Algorithms for NTRK Fusion Testing

Gregory J. Riely, MD, PhD, on Identifying Patients With NTRK Fusions

Alexander Drilon, MD: Where Can NTRK Fusions Be Found?

View More

Advertisement

JNCCN Spotlights

Larotrectinib

Entrectinib

Identifying an NTRK Gene Fusion

View More

More

News

AACR 2023: Concordance Between Tissue-Based Testing Methods for Identifying NTRK Gene Fusion

AACR 2023: Finnish Population–Based Study of NTRK Gene Fusions in Solid Tumors

Next-Generation TRK Inhibitor Under Study in NTRK Fusion–Positive Solid Tumors

AACR 2023: Study Identified Common Genetic Mutations Across Various Cancer Types

AACR 2023: Researchers Identify Cell Signaling Pathways Activated by ETV6::NTRK3 Fusions

Acquired Resistance to Entrectinib in Pancreatic Neuroendocrine Tumor: Case Report

Impact of Genetic Differences in Treatment Response Among Black Individuals With Pancreatic Cancer

What Do Head and Neck Mesenchymal Tumors With Kinase Fusions Look Like Histologically?

View More

Advertisement

Published

Medical Literature

Age-Dependent Biologic Consequences of NTRK and RET Gene Fusions in Thyroid Cancer

NTRK Gene Fusions in Undifferentiated Sarcomas in Pediatric Patients

RET/NTRK Fusions and Risk of Metastasis in Pediatric Differentiated Thyroid Cancer

Brain Metastasis Model of NTRK-Rearranged Tumors: Focus on Treatment Resistance

View More

Ongoing

CE Activities

Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC

Trekking Through the Latest Updates for ROS1-Targeted Therapies

Navigating the Latest Data on NTRK-Targeted Therapies

Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!

View More

Available

Clinical Trials

Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I–III NSCLC With ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations

A Phase I/II, Open-Label, Multicenter, First-in-Human Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1–3 Rearrangements (TRIDENT-1)

A Phase I/II Study of Repotrectinib in Children and Young Adults With Advanced or Metastatic Cancers Containing ALK, ROS1, or NTRK1–3 Alterations

Genetic Testing in Guiding Treatment of Patients With Brain Metastases

View More

Resources

For Cancer Care

The ASCO Post Video Roundtable: Updates in Lung Cancer

NCCN Biomarkers Compendium

NTRKers

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.